Table 4 Clinicopathologic characteristics between breast cancer patients with/without brain metastasis
From: Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence
Character | All | Â | Â | |
|---|---|---|---|---|
Distant metastasis | HR (95% CI) | P-value | ||
no | yes | |||
Age (mean ± SD, years) | 47.6 (9.66) | 42.5 (6.22) | 0.94 (0.874–1.01) | 0.099 |
Family history of BC | ||||
 Yes | 6 (4.84%) | 0 (0.00%) | 3.84e-08 (0-Inf) | 0.998 |
 No | 118 (95.16%) | 10 (100.00%) | ||
Breast-feeding histories | ||||
 Yes | 108 (87.10%) | 7 (70.00%) | 0.375 (0.097–1.45) | 0.156 |
 No | 16 (12.90%) | 3 (30.00%) | ||
Marital status | ||||
 Married | 122 (98.39%) | 9 (90.00%) | 0.214 (0.0271–1.69) | 0.143 |
 Never married | 2 (1.61%) | 1 (10.00%) | ||
Abortion | ||||
 Yes | 76 (61.29%) | 4 (40.00%) | 0.44 (0.124–1.56) | 0.203 |
 No | 48 (38.71%) | 6 (60.00%) | ||
Reproductive history | ||||
 Yes | 118 (95.16%) | 9 (90.00%) | 0.515 (0.0652–4.06) | 0.528 |
 No | 6 (4.84%) | 1 (10.00%) | ||
Menstrual status | ||||
 Menstruate | 78 (62.90%) | 8 (80.00%) | 0.434 (0.0922–2.05) | 0.292 |
 Menopause | 46 (37.10%) | 2 (20.00%) | ||
Age of menarche | 14.5 (1.73) | 13.6 (1.51) | 0.71 (0.465–1.08) | 0.113 |
Lymph node metastasis | ||||
 Have | 30 (24.19%) | 5 (50.00%) | 2.99 (0.866–10.3) | 0.083 |
 None | 94 (75.81%) | 5 (50.00%) | ||
molecular subtyping | ||||
 1 | 13 (10.48%) | 0 (0.00%) | 1.59 (0.856–2.97) | 0.141 |
 2 | 85 (68.55%) | 6 (60.00%) | ||
 3 | 6 (4.84%) | 1 (10.00%) | ||
 4 | 20 (16.13%) | 3 (30.00%) | ||
ER | ||||
 Positive | 98 (79.03%) | 4 (40.00%) | 0.197 (0.0557–0.7) | 0.012 |
 Negative | 26 (20.97%) | 6 (60.00%) | ||
PR | ||||
 Positive | 95 (76.61%) | 5 (50.00%) | 0.33 (0.0956–1.14) | 0.080 |
 Negative | 29 (23.39%) | 5 (50.00%) | ||
HER2 status | ||||
 Positive | 84 (67.74%) | 6 (60.00%) | 1.27 (0.559–2.9) | 0.565 |
 Negative | 40 (32.26%) | 4 (40.00%) | ||
Ki-67 | ||||
 Positive | 109 (87.90%) | 10 (100.00%) | 1.01 (0.983–1.03) | 0.523 |
 Negative | 15 (12.10%) | 0 (0.00%) | ||
TPSA | ||||
 Positive | 13 (10.48%) | 2 (20.00%) | 2.12 (0.451–10) | 0.341 |
 Negative | 111 (89.52%) | 8 (80.00%) | ||
CA153 | ||||
 Positive | 1 (0.81%) | 4 (40.00%) | 35.7 (9.63–132) |  < 0.001 |
 Negative | 123 (99.19%) | 6 (60.00%) | ||
CEA | ||||
 Positive | 1 (0.81%) | 2 (20.00%) | 18.2 (3.81–86.9) |  < 0.001 |
 Negative | 123 (99.19%) | 8 (80.00%) | ||
CA125 | ||||
 Positive | 8 (6.45%) | 3 (30.00%) | 5.5 (1.42–21.3) | 0.013 |
 Negative | 116 (93.55%) | 7 (70.00%) | ||
Operation | ||||
 No surgery | 0 (0.00%) | 2 (20.00%) | 0.573 (0.177–1.86) | 0.353 |
 Conserving | 55 (44.35%) | 2 (20.00%) | ||
 Radical | 69 (55.65%) | 6 (60.00%) | ||
Endocrinotherapy | ||||
 Yes | 12 (9.68%) | 0 (0.00%) | 1.3e-08 (0-Inf) | 0.998 |
 No | 112 (90.32%) | 10 (100.00%) | ||
Radiotherapy | ||||
 Yes | 17 (13.71%) | 3 (30.00%) | 2.66 (0.687–10.3) | 0.157 |
 No | 107 (86.29%) | 7 (70.00%) | ||
Chemotherapy | ||||
 Yes | 113 (91.13%) | 10 (100.00%) | 75,600,000 (0-Inf) | 0.998 |
 No | 11 (8.87%) | 0 (0.00%) | ||
RadScore (mean ± SD) | -2.82 (0.53) | -1.72 (0.11) | 0.356 |  < 0.001 |